NEUP · Bull vs Bear

The case for and the case against Neuphoria Therapeutics Inc., each point drawn from public SEC filings — who’s buying, the red flags, and the health score. No opinion, no price call. Read both sides, then pick yours.

the bull case // 0

No recent buying across insiders, Congress, or 13F filers, and no standout strength in the filing-based scores. A quiet bull case — not the same as a bear case.

the bear case // 3

Going-concern warning

Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.

SEC filing ↗

Active dilution shelf

An effective S-3 shelf with 5 prospectus filing(s) in 12 months — shares may be getting sold into the market.

SEC filing ↗

Weak price momentum

-36.5% vs 200-day

SEC XBRL

where do you land on NEUP?

Bull Bear

Saved on this device. Your call, from the evidence above — not a recommendation.

Educational only — not financial adviceand never a recommendation to buy or sell. Both sides are built from public SEC filings (Form 4, STOCK Act, 13F, XBRL financials), which lag 40–90 days; absence of a red flag is not a clean bill of health.